These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37437090)

  • 1. Response to: Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized, Controlled Trial.
    Trinh A; Milat F
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e418-e419. PubMed ID: 37437090
    [No Abstract]   [Full Text] [Related]  

  • 2. Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized Controlled Trial.
    Granild-Jensen JB; Møller-Madsen B; Rackauskaite G; Farholt S; Søndergaard C; Sørensen TH; Vestergaard ET; Langdahl BL
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2840-2851. PubMed ID: 37235798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual Injection of Zoledronic Acid Improves Bone Status in Children with Cerebral Palsy and Rett Syndrome.
    Wiedemann A; Renard E; Hernandez M; Dousset B; Brezin F; Lambert L; Weryha G; Feillet F
    Calcif Tissue Int; 2019 Apr; 104(4):355-363. PubMed ID: 30554334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractures in children with cerebral palsy.
    Mughal MZ
    Curr Osteoporos Rep; 2014 Sep; 12(3):313-8. PubMed ID: 24964775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate use in children with cerebral palsy.
    Hurley T; Zareen Z; Stewart P; McDonnell C; McDonald D; Molloy E
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD012756. PubMed ID: 34224134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
    Huang J; Meixner L; Fernandez S; McCutchan JA
    AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    J Bone Miner Res; 2022 Jan; 37(1):3-11. PubMed ID: 34585780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.
    Mamtani M; Kulkarni H
    Osteoporos Int; 2010 Jan; 21(1):183-7. PubMed ID: 19242634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED; Perry CM
    Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
    Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
    Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
    J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone structure and remodelling in stroke patients: early effects of zoledronate.
    Poole KE; Vedi S; Debiram I; Rose C; Power J; Loveridge N; Warburton EA; Reeve J; Compston J
    Bone; 2009 Apr; 44(4):629-33. PubMed ID: 19121416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis.
    Agnello KA; Trumble TN; Chambers JN; Seewald W; Budsberg SC
    Am J Vet Res; 2005 Sep; 66(9):1487-95. PubMed ID: 16261820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.